AIM: To evaluate the prevalence of autoantibodies in chronic hepatitis C virus (HCV)-infected children focusing on thyroid autoimmunity. METHODS: We investigated the prevalence of auto-antibodies in 123 chronic HCV-infected children before, during and after monotherapy with interferon-alpha (IFN-alpha) or combined treatment with interferon-alpha or peginterferon-alpha and ribavirin. Besides antibodies against smooth muscle (SMA), nuclei (ANA), and liver/kidney microsomes (LKM), the incidence of anti-thyroid peroxidase antibodies as well as thyroid function parameters (TSH, FT3 and FT4) were determined. RESULTS: We found that 8% of children had autoantibodies before treatment. During treatment, 18% of children were found positive for at least one autoantibody; 15.5% of children developed pathologic thyroid values during IFN-alpha treatment compared to only one child before therapy. Six children had to be substituted while developing laboratory signs of hypothyroidism. CONCLUSION: Our data indicate a strong correlation between interferon-alpha treatment and autoimmune phenomena, notably the emergence of thyroid antibodies. The fact that some children required hormone replacement underlines the need of close monitoring in particularly those who respond to therapy and have to be treated for more than 6 mo.
AIM: To evaluate the prevalence of autoantibodies in chronic hepatitis C virus (HCV)-infected children focusing on thyroid autoimmunity. METHODS: We investigated the prevalence of auto-antibodies in 123 chronic HCV-infectedchildren before, during and after monotherapy with interferon-alpha (IFN-alpha) or combined treatment with interferon-alpha or peginterferon-alpha and ribavirin. Besides antibodies against smooth muscle (SMA), nuclei (ANA), and liver/kidney microsomes (LKM), the incidence of anti-thyroid peroxidase antibodies as well as thyroid function parameters (TSH, FT3 and FT4) were determined. RESULTS: We found that 8% of children had autoantibodies before treatment. During treatment, 18% of children were found positive for at least one autoantibody; 15.5% of children developed pathologic thyroid values during IFN-alpha treatment compared to only one child before therapy. Six children had to be substituted while developing laboratory signs of hypothyroidism. CONCLUSION: Our data indicate a strong correlation between interferon-alpha treatment and autoimmune phenomena, notably the emergence of thyroid antibodies. The fact that some children required hormone replacement underlines the need of close monitoring in particularly those who respond to therapy and have to be treated for more than 6 mo.
Authors: M Lenzi; P J Johnson; I G McFarlane; G Ballardini; H M Smith; B M McFarlane; C Bridger; D Vergani; F B Bianchi; R Williams Journal: Lancet Date: 1991-08-03 Impact factor: 79.321
Authors: L Todros; G Saracco; M Durazzo; M L Abate; G Touscoz; L Scaglione; G Verme; M Rizzetto Journal: Hepatology Date: 1995-11 Impact factor: 17.425
Authors: J Matsuda; N Saitoh; M Gotoh; K Gohchi; M Tsukamoto; S Syoji; K Miyake; M Yamanaka Journal: Am J Gastroenterol Date: 1995-07 Impact factor: 10.864
Authors: Paolo Muratori; Luigi Muratori; Gabriella Verucchi; Luciano Attard; Francesco B Bianchi; Marco Lenzi Journal: Clin Infect Dis Date: 2003-10-13 Impact factor: 9.079
Authors: D Preziati; L La Rosa; G Covini; R Marcelli; S Rescalli; L Persani; E Del Ninno; P L Meroni; M Colombo; P Beck-Peccoz Journal: Eur J Endocrinol Date: 1995-05 Impact factor: 6.664
Authors: Hermann E Wasmuth; Christian Stolte; Andreas Geier; Christoph G Dietrich; Carsten Gartung; Johann Lorenzen; Siegfried Matern; Frank Lammert Journal: BMC Infect Dis Date: 2004-02-13 Impact factor: 3.090
Authors: Mohammed E Hamed; Naglaa M Kamal Alanani; Laila M Sherief; Mohammed A Fouad; Lamiaa A Elwahab; Nermin Raafat Journal: Saudi J Gastroenterol Date: 2013 Nov-Dec Impact factor: 2.485